Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8409948 | 0.88 | TDP1 (0.42) | TDP1MEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL5146402 | 0.86 | TDP1 (0.37) | TDP1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL7029641 | 0.85 | ZDHHC7 (0.43) | TDP1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL31610 | 0.84 | TDP1 (0.47) | TDP1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL717299 | 0.83 | ALDH1A1 (0.40) | TDP1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL27008515 | 0.82 | L3MBTL1 (0.49) | TDP1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL27321299 | 0.82 | TDP1 (0.46) | TDP1MEN1KMT2AALDH1A1POLB | |
| Ammonia Solution, Strong SCHEMBL15710720 | 0.82 | TDP1 (0.46) | TDP1MEN1KMT2AALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL27504364 | 0.82 | TDP1 (0.46) | TDP1MEN1KMT2AALDH1A1POLB | |
| SCHEMBL27324536 | 0.80 | TDP1 (0.44) | TDP1MEN1KMT2AALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1880998-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2008-01-23 | — | — | EP | disclosed |
| US-7301031-B2 | Methods for producing hydroxy amino acids, esters, and derivatives thereof | BIOCATALYTICS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-7271170-B2 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271170-B2 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271170-B2 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1648899-B1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1560822-B1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORP (US) | 2006-08-09 | — | — | EP | disclosed |
| US-6951864-B2 | 4-imidazol-1-ylmethyl-pyrimidine derivatives | NEUROGEN CORP. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20050192439-A1 | Methods for producing hydroxy amino acids, esters, and derivatives thereof | CODEXIS, INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1560822-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES AS LIGANDS FOR GABAA RECEPTORS | Neurogen Corporation (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050100993-A1 | Methods for producing hydroxy amino acids and derivatives thereof | BIOCATALYTICS, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050038043-A1 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005012306-A2 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
| US-6833471-B2 | Contacting beta-ketodiester having ketone and two esters with a ketoreductase under conditions permitting reduction of ketone to alcohol, regioselectively hydrolyzing one of ester groups to acid, converting acid or ester to amine | BIOCATALYTICS, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-05-27 | — | — | US | disclosed |
| WO-2004041808-A1 | 4-IMIDAZOL-1-YLMETHYL-PYRIMIDINE DERIVATIVES_AS LIGANDS FOR GABAA RECEPTORS | NEUROGEN CORPORATION (GB) | 2004-05-21 | — | — | WO | disclosed |
| US-20040053377-A1 | Methods for producing hydroxy amino acids and derivatives thereof | CODEXIS, INC. | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053377-A1 | Methods for producing hydroxy amino acids and derivatives thereof | HMGCR, HSD17B12, BCKDK | TDP1 2164/4885MEN1 4215/4885KMT2A 1691/4885 |
| US-20040102457-A1 | 4-Imidazol-1-ylmethyl pyrimidine derivatives | GABRA1, GABRA4, GABRA3 | TDP1 1129/4885MEN1 4538/4885KMT2A 2274/4885 |
| US-20050100993-A1 | Methods for producing hydroxy amino acids and derivatives thereof | ALDH7A1, BCKDK, HSD17B12 | TDP1 2778/4885MEN1 3827/4885KMT2A 548/4885 |
| US-20050192439-A1 | Methods for producing hydroxy amino acids, esters, and derivatives thereof | ALDH7A1, BCKDK, ADH5 | TDP1 3149/4885MEN1 4144/4885KMT2A 1034/4885 |
| US-20050038043-A1 | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | GABRA3, GABRA1, GABBR1 | TDP1 1301/4885MEN1 4323/4885KMT2A 3001/4885 |
| US-20080139580-A1 | IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS | GABRA3, GABRA1, GABBR1 | TDP1 1301/4885MEN1 4323/4885KMT2A 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.